	US 12,486,316 B1
	Antibodies that bind the spike protein of SARS-CoV-2
Taylor Cohen, Wilmington, DE (US); Joe Francica, Wilmington, DE (US); Saravan Rajan, Wilmington, DE (US); Gilad Kaplan, Gaithersburg, MD (US); YingYun Cai, Wilmington, DE (US); and Andrew Dippel, Gaithersburg, MD (US)
Assigned to AstraZeneca UK Limited, Cambridge (GB)
Filed by ASTRAZENECA UK LIMITED, Cambridge (GB)
Filed on Feb. 20, 2025, as Appl. No. 19/058,780.
Application 19/058,780 is a continuation of application No. 18/861,365, previously published as PCT/EP2023/061297, filed on Apr. 28, 2023.
Claims priority of provisional application 63/371,454, filed on Aug. 15, 2022.
Claims priority of provisional application 63/336,332, filed on Apr. 29, 2022.
Int. Cl. C07K 16/10 (2006.01)

CPC C07K 16/1003 (2023.08) [C07K 2317/33 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

15 Claims

1. An antibody or antigen-binding fragment thereof that specifically binds to the spike protein of SARS-COV-2, wherein the antibody or antigen-binding fragment comprises the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 of SEQ ID NOs: 31, 32, 37, 34, 35, and 36, respectively.